These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1009 related items for PubMed ID: 31693324

  • 1.
    Chao YS, Loshak H.
    ; 2019 04 17. PubMed ID: 31693324
    [Abstract] [Full Text] [Related]

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F, Polymeros D, Panagiotou M, Theodoropoulos K, Rigopoulos D.
    Acta Dermatovenerol Croat; 2016 Apr 17; 24(1):83-5. PubMed ID: 27149138
    [Abstract] [Full Text] [Related]

  • 3. Update on the Use of Biologic Therapy in Ulcerative Colitis.
    Aggarwal A, Sabol T, Vaziri H.
    Curr Treat Options Gastroenterol; 2017 Mar 17; 15(1):155-167. PubMed ID: 28120279
    [Abstract] [Full Text] [Related]

  • 4. A comprehensive review and update on Crohn's disease.
    Gajendran M, Loganathan P, Catinella AP, Hashash JG.
    Dis Mon; 2018 Feb 17; 64(2):20-57. PubMed ID: 28826742
    [Abstract] [Full Text] [Related]

  • 5. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ, Jensen CB, Wennerström C, Burisch J, Petersen J.
    Scand J Gastroenterol; 2023 Jul 17; 58(7):726-736. PubMed ID: 36802972
    [Abstract] [Full Text] [Related]

  • 6. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
    Wilson M, Lucas A, Cameron A, Luo M.
    Am Health Drug Benefits; 2018 Jul 17; 11(5):253-262. PubMed ID: 30464793
    [Abstract] [Full Text] [Related]

  • 7. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC, de Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC.
    World J Gastroenterol; 2019 Mar 07; 25(9):1142-1157. PubMed ID: 30863001
    [Abstract] [Full Text] [Related]

  • 8. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.
    United European Gastroenterol J; 2015 Oct 07; 3(5):419-28. PubMed ID: 26535119
    [Abstract] [Full Text] [Related]

  • 9. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE, Benchimol EI, Bernstein CN, Singh H, Tennakoon A, Zubieta AA, Coward S, Jones J, Kaplan GG, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN.
    J Crohns Colitis; 2020 Oct 05; 14(10):1354-1363. PubMed ID: 32648579
    [Abstract] [Full Text] [Related]

  • 10. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.
    Rawla P, Sunkara T, Raj JP.
    J Inflamm Res; 2018 Oct 05; 11():215-226. PubMed ID: 29844695
    [Abstract] [Full Text] [Related]

  • 11. Current therapy of inflammatory bowel disease in children.
    Rufo PA, Bousvaros A.
    Paediatr Drugs; 2006 Oct 05; 8(5):279-302. PubMed ID: 17037946
    [Abstract] [Full Text] [Related]

  • 12. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y, Paramsothy S, Yau Y, Leong RW.
    Aliment Pharmacol Ther; 2021 Aug 05; 54(3):292-301. PubMed ID: 34151447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Update on the management of ulcerative colitis.
    Taba Taba Vakili S, Taher M, Ebrahimi Daryani N.
    Acta Med Iran; 2012 Aug 05; 50(6):363-72. PubMed ID: 22837114
    [Abstract] [Full Text] [Related]

  • 17. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G, Daperno M.
    Curr Gastroenterol Rep; 2006 Dec 05; 8(6):506-12. PubMed ID: 17105690
    [Abstract] [Full Text] [Related]

  • 18. 10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study.
    Koo HM, Jun YK, Choi Y, Shin CM, Park YS, Kim N, Lee DH, Shin YK, Yoon H.
    Therap Adv Gastroenterol; 2023 Dec 05; 16():17562848231201728. PubMed ID: 37786473
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
    Clarke K, Chintanaboina J.
    Clin Rev Allergy Immunol; 2019 Oct 05; 57(2):179-193. PubMed ID: 29754190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.